The raised revenue guidance is a modest positive, but the lowered gross margin guidance and continued GAAP losses create a mixed picture. Monitor the Q1 2027 completion of the Holliston plant closure for cost savings realization, and watch for the signing of a second large distributor agreement mentioned as a 2026 target, which could expand pharma access.
Price Chart
Executive Summary
Harvard Bioscience filed an 8-K with an investor presentation providing updated FY26 guidance: revenue growth raised to 3%-5% (from 2%-4%), but adjusted gross margin guidance lowered to 57%-59% (from 58%-60%). The presentation also disclosed 2Q26 GAAP revenue of $22.7M (+11% YoY) and adjusted EBITDA of $1.7M, alongside details on a $40M debt refinancing generating $3M in annual cash savings and a manufacturing consolidation expected to deliver $3-4M in EBITDA improvements by 2028. The raised revenue guidance is a modest positive, but the lowered gross margin guidance tempers the outlook, and the company remains GAAP-net-loss-making with a GAAP operating loss of $978K in 2Q26.
Key Facts
- FY26 revenue growth guidance raised to 3%-5% from 2%-4%
- FY26 adjusted gross margin guidance lowered to 57%-59% from 58%-60%
- 2Q26 GAAP revenue $22.7M, up 11% YoY (10% on constant currency)
- 2Q26 GAAP net loss of $2.9M vs $2.3M loss in 2Q25
- 2Q26 adjusted EBITDA of $1.7M, up from $1.5M in 2Q25
- Debt refinancing extended maturity to 2029, generating $3M annual cash savings
- Manufacturing consolidation (Project Viking) expected to deliver $3M EBITDA improvement in FY27 and $4M from FY28 onward
- FY25 revenue of $87M with 58% adjusted gross margin and $8M adjusted EBITDA
- 54% recurring revenue in FY25 with path to 60%+
Financial Impact
FY26 revenue growth raised to 3-5% (from 2-4%), but gross margin guidance lowered to 57-59% (from 58-60%). 2Q26 revenue $22.7M (+11% YoY), GAAP net loss $2.9M, adjusted EBITDA $1.7M.
Risk Factors
- Lowered gross margin guidance (57-59% vs prior 58-60%) suggests margin pressure
- Continued GAAP net losses ($2.9M in 2Q26) and negative operating cash flow
- High net debt of $33.5M with expensive debt (12.8% interest rate) and 10% exit fee on refinancing
- Manufacturing consolidation execution risk and potential customer disruption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-005406 |
| Document: f8k_081126.htm | 0001171843-26-005406 |
| Document: 0001171843-26-005406-index-headers.html | 0001171843-26-005406 |
| Document: 0001171843-26-005406-index.html | 0001171843-26-005406 |
| Document: 0001171843-26-005406.txt | 0001171843-26-005406 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | SC 13G/A | $7.92 | awaiting T+60 | — | $8.32 (+5.05%) |
Aug 11, 2026 10w ago | 8-K | $6.13 | awaiting T+60 | — | $8.32 (+35.73%) |
Aug 11, 2026 10w ago | 8-K | $6.13 | awaiting T+60 | — | $8.32 (+35.73%) |
Jul 28, 2026 12w ago | Press Release | $5.92 | awaiting T+60 | — | $8.32 (+40.54%) |
Jun 2, 2026 20w ago | 8-K | $6.50 $7.90 | ▲ +21.54% | ▲ +19.04% | $8.32 (+28.00%) |
May 12, 2026 23w ago | 8-K | $5.41 $6.19 | ▲ +14.42% | ▲ +10.03% | $8.32 (+53.79%) |
May 12, 2026 23w ago | 8-K | $5.41 $6.19 | ▼ −14.42% | ▼ −10.03% | $8.32 (−53.79%) |
May 12, 2026 23w ago | Press Release | $5.41 $6.19 | ▲ +14.42% | ▲ +10.03% | $8.32 (+53.79%) |
Mar 16, 2026 32w ago | Insider Cluster | $5.01 $6.01 | ▲ +19.96% | ▲ +9.48% | $8.32 (+66.07%) |
Mar 16, 2026 32w ago | Insider Cluster | $5.01 $6.01 | ▲ +19.96% | ▲ +9.48% | $8.32 (+66.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers